Twenty-one analysts covering Bristol Myers Squibb have delivered a consensus recommendation of Hold. Within that group, one analyst rates the stock a Sell, thirteen maintain Hold opinions and seven recommend Buy. Over the past year, analysts’ average 12-month price target stands at $56.86, reflecting modest upside potential relative to current trading levels.

In October, Weiss Ratings reaffirmed a Hold (C-) assessment. Shortly thereafter, HSBC reiterated its Hold view and set a $53 objective. On November 8, Wall Street Zen upgraded the stock from Buy to Strong-Buy, signaling increased conviction in upcoming trial readouts. Morgan Stanley maintained an Underweight stance on December 12 but lifted its valuation target from $36 to $37, reflecting confidence in cash flow stability. DBS Bank raised its rating to Moderate Buy in early October ahead of the firm’s guidance update.

Institutional activity has been pronounced among smaller asset managers: Trifecta Capital Advisors and Darwin Wealth Management each initiated new positions in the second quarter valued at approximately $25,000. Harbor Capital Advisors more than doubled its stake during the third quarter to 605 shares, a 107.2% increase, representing about $27,000. REAP Financial Group expanded its holdings by 202.8% to 639 shares, valued at $30,000, and KERR Financial Planning entered with a $35,000 position. Overall, institutions and hedge funds control roughly 76.4% of outstanding shares.

In its latest report, Bristol Myers Squibb posted quarterly revenue of $12.22 billion, topping consensus by $470 million and marking a 2.8% year-over-year increase. Earnings per share of $1.63 beat estimates by $0.11. The company’s return on equity reached 76.5%, with a net margin of 12.6%. Management set full-year guidance at $6.40–$6.60 EPS, above the $6.22 consensus. A quarterly dividend of $0.63 per share was announced, representing a 1.6% increase and yielding 4.6% on an annualized basis, with a payout ratio of 85.1%.